HSGC(SH:600774)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥357,286,603.21, representing a decrease of 3.02% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥23,258,554.56, an increase of 4.13% year-over-year[3]. - Total revenue for Q1 2022 was CNY 357.29 million, a decrease of 3.03% from CNY 368.40 million in Q1 2021[18]. - Operating profit for Q1 2022 was CNY 22.81 million, compared to CNY 28.11 million in Q1 2021, reflecting a decline of 18.93%[18]. - Net profit for Q1 2022 was CNY 16.51 million, down from CNY 20.11 million in Q1 2021, a decrease of 17.73%[18]. - Net profit for Q1 2022 was ¥16,513,662.17, a decrease of 18.0% compared to ¥20,113,177.22 in Q1 2021[19]. - Revenue from sales of goods and services in Q1 2022 was ¥489,458,093.51, down 19.7% from ¥609,462,096.53 in Q1 2021[22]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥7,030,251.48, a significant decrease of 118.9% compared to the previous year[3]. - Operating cash flow for Q1 2022 showed a net outflow of ¥7,030,251.48, contrasting with a net inflow of ¥37,189,788.78 in Q1 2021[22]. - Cash and cash equivalents increased to CNY 399.45 million as of March 31, 2022, up from CNY 272.21 million at the end of 2021, representing a growth of 46.81%[12]. - Cash and cash equivalents at the end of Q1 2022 increased to ¥456,648,230.29 from ¥148,393,584.61 at the end of Q1 2021, marking a significant improvement[23]. - The company reported a net cash inflow from financing activities of ¥139,778,363.46 in Q1 2022, compared to a net outflow of ¥212,953,231.33 in Q1 2021[23]. - Cash flow from investment activities showed a net outflow of ¥5,501,012.35 in Q1 2022, compared to a net outflow of ¥5,244,103.50 in Q1 2021[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,389,872,276.14, an increase of 4.30% from the end of the previous year[3]. - Total assets as of March 31, 2022, amounted to ¥2,481,045,568.01, an increase from ¥2,374,921,744.36 at the end of 2021[26]. - Total liabilities increased to CNY 1.58 billion as of March 31, 2022, compared to CNY 1.46 billion at the end of 2021, an increase of 8.51%[14]. - Total liabilities as of March 31, 2022, amounted to CNY 977,341,271.28, an increase from CNY 872,481,850.63 at the end of 2021[27]. - Short-term borrowings increased to CNY 233,308,095.89 from CNY 208,297,249.21 at the end of 2021[27]. - Long-term borrowings rose significantly to CNY 278,530,000.00 from CNY 69,790,000.00 at the end of 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,242[6]. - The top shareholder, Wuhan Hanyang Investment Development Group Co., Ltd., held 26.93% of the shares[8]. - Shareholders' equity rose to CNY 1.81 billion as of March 31, 2022, compared to CNY 1.79 billion at the end of 2021, reflecting an increase of 0.86%[14]. - Total equity as of March 31, 2022, was CNY 1,503,704,296.73, slightly up from CNY 1,502,439,893.73 at the end of 2021[27]. Expenses - Research and development expenses increased by 58.44%, primarily due to increased R&D spending by the subsidiary Dikon Pharmaceutical[5]. - The company reported a decrease in sales expenses to CNY 9,542,512.19 from CNY 8,171,166.21 in Q1 2021[28]. - Financial expenses decreased significantly to CNY 5,418,457.83 from CNY 11,081,500.83 in Q1 2021, with interest expenses dropping to CNY 8,562,826.72 from CNY 14,056,064.22[28]. Earnings Per Share - Basic earnings per share decreased by ¥0.0237 to ¥0.0788[3]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.0788, down from ¥0.0984 in Q1 2021, reflecting a decline of 20.0%[19]. - The weighted average return on equity decreased by 2.03 percentage points to 1.29%[3].